III-16

N/A

Report date: 2022/04/28 10:26:50
NME

Base Information

Drug NameIII-16
Drug Alias NameIII-16
ClassificationOther
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitorsBromodomain-containing protein 4 inhibitors
TargetsPoly (ADP-Ribose) polymeraseBromodomain-containing protein 4
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChina Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesChina Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A